Skip to main content
ORTIN GLOBAL LIMITED logo

ORTIN GLOBAL LIMITED — Investor Relations & Filings

Ticker · ORTINGLOBE ISIN · INE749B01020 BSE.NS Manufacturing
Open in API
Filings indexed 203 across all filing types
Latest filing 2026-02-14 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS ORTINGLOBE

About ORTIN GLOBAL LIMITED

https://www.ortinlabsindia.com/

Ortin Global Limited is a pharmaceutical enterprise engaged in the development, manufacture, and marketing of active pharmaceutical ingredients (APIs), intermediates, and finished dosage formulations. The company maintains a diverse product portfolio covering various therapeutic segments, such as anti-diabetics, anti-hypertensives, anti-retrovirals, analgesics, and anti-pyretics. Its operations include the synthesis of complex chemical molecules and the production of oral solids and liquids, including tablets, capsules, and syrups. With a focus on integrated manufacturing processes, the company serves both domestic and international healthcare markets. Ortin Global Limited prioritizes research and development to expand its product offerings and optimize production techniques, ensuring compliance with established quality standards across its manufacturing facilities.

Recent filings

Filing Released Lang Actions
Integrated Filing- Financial
Interim / Quarterly Report Classification · 97% confidence The document is an official communication under SEBI LODR Regulations containing the full unaudited financial statements for the quarter and nine-months ended December 31, 2025, along with the statutory auditor’s limited review report. It clearly presents detailed quarterly financial data (income statement, EPS calculations, notes) rather than a mere summary announcement. This meets the definition of an Interim / Quarterly Report, not a brief earnings release or simple announcement. Q3 2025
2026-02-14 English
Open Offer
Regulatory Filings
2026-02-11 English
Board Meeting — Financial Results/Other business matters
Board/Management Information Classification · 95% confidence The document is a formal notice addressed to stock exchanges about an upcoming Board Meeting scheduled for 14.02.2026. It mentions that the Board will consider un-audited financial results for the quarter and nine months ended 31.12.2025. The document is short (1714 characters) and serves as an intimation or announcement of a meeting rather than containing any financial data or results itself. It is not a full financial report, earnings release, or management discussion. It is also not a certification or voting result. The document fits the category of Board/Management Information (MANG) as it relates to the scheduling and agenda of a board meeting, which is a management-level announcement.
2026-02-05 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a compliance certificate issued under Regulation 74(5) of SEBI (Depositories & Participants) Regulations, 2018, for the quarter ended 31.12.2025. It is addressed to stock exchanges and certifies that details of securities dematerialized/rematerialized have been furnished as required. The document is a regulatory compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements or detailed financial data. The document length is 3770 characters, which is relatively short and focused on regulatory compliance. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2026-01-13 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the closure of the trading window under SEBI (Prohibition of Insider Trading) Regulations, 2015. It mentions the upcoming declaration of unaudited financial results for the quarter ending 31.12.2025 and the scheduled Board Meeting to approve these results. The document does not contain any financial data or results itself, nor does it present a report. It is an announcement related to insider trading compliance and trading restrictions ahead of financial results disclosure. The document length is short (2197 characters), and it serves as a regulatory notification rather than a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance and regulatory announcements that do not fit other specific categories.
2025-12-26 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 83% confidence The document is an outcome-of-board-meeting notification filed under SEBI LODR Regulations 30 & 33, which includes the full unaudited financial results and limited review report for the quarter and half-year ended 30.09.2025. It contains substantive financial statements (detailed P&L data) rather than just highlights or a link to a report. This matches the definition for an Interim/Quarterly Report. H1 2026
2025-11-14 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.